CTRP4/interleukin-6 receptor signaling ameliorates autoimmune encephalomyelitis by suppressing Th17 cell differentiation

J Clin Invest. 2023 Nov 28;134(4):e168384. doi: 10.1172/JCI168384.

Abstract

C1q/TNF-related protein 4 (CTRP4) is generally thought to be released extracellularly and plays a critical role in energy metabolism and protecting against sepsis. However, its physiological functions in autoimmune diseases have not been thoroughly explored. In this study, we demonstrate that Th17 cell-associated experimental autoimmune encephalomyelitis was greatly exacerbated in Ctrp4-/- mice compared with WT mice due to increased Th17 cell infiltration. The absence of Ctrp4 promoted the differentiation of naive CD4+ T cells into Th17 cells in vitro. Mechanistically, CTRP4 interfered with the interaction between IL-6 and the IL-6 receptor (IL-6R) by directly competing to bind with IL-6R, leading to suppression of IL-6-induced activation of the STAT3 pathway. Furthermore, the administration of recombinant CTRP4 protein ameliorated disease symptoms. In conclusion, our results indicate that CTRP4, as an endogenous regulator of the IL-6 receptor-signaling pathway, may be a potential therapeutic intervention for Th17-driven autoimmune diseases.

Keywords: Autoimmunity; Cellular immune response.

MeSH terms

  • Adipokines / metabolism
  • Animals
  • Cell Differentiation
  • Complement C1q
  • Encephalomyelitis*
  • Encephalomyelitis, Autoimmune, Experimental*
  • Immunologic Factors
  • Interleukin-6 / genetics
  • Interleukin-6 / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Receptors, Interleukin-6 / genetics
  • Receptors, Interleukin-6 / metabolism
  • Th17 Cells

Substances

  • Interleukin-6
  • Complement C1q
  • Immunologic Factors
  • Receptors, Interleukin-6
  • Ctrp4 protein, mouse
  • Adipokines